Monday, October 16, 2006

NJ Mass Tort Designation for Risperdal, Seroquel, and Zyprexa

Last month, New Jersey centralized its state court litigation over the anti-psychotic drugs Risperdal, Seroquel, and Zyprexa.  Here's the Notice to the Bar and the accompanying announcement:

On September 11, 2006, the Supreme Court designated all litigation, pending and future, statewide involving the drugs, Risperdal, Seroquel and Zyprexa as mass tort and assigned it for centralized, coordinated handling to the Hon. Bryan D. Garruto in the Middlesex vicinage. This litigation involves claims filed largely against the manufacturers of these pharmaceuticals for alleged damages and injuries arising from their use.

The state supreme court designated litigation over the three drugs as a single mass tort "for coordinated and centralized management purposes."  By contrast, in the federal courts, the Judicial Panel on Multidistrict Litigation designated separate MDL's for Zyprexa (E.D.N.Y.) and Seroquel (M.D. Fla.).


Zyprexa | Permalink

TrackBack URL for this entry:

Listed below are links to weblogs that reference NJ Mass Tort Designation for Risperdal, Seroquel, and Zyprexa:

» October 17 round-up from Overlawyered
Interview with ICJL's Ed Murnane on Madison County judiciary elections. [Madison County Record; see also Illinois Justice Blog] London pension fund: oops, we just sued BP [Point of Law] New York court throws out mold... [Read More]

Tracked on Oct 17, 2006 4:31:04 AM


Post a comment